{"publish_date":{"20202033":20151116,"20185543":20151116,"20218216":20151116,"20205539":20151116,"20178537":20151116,"20179937":20151116,"20179938":20151116,"20198912":20151116,"20184287":20151116,"20205842":20151116,"20198633":20151116,"20193708":20151116},"url":{"20202033":"http:\/\/www.independent.co.ug\/features\/features\/10790-hepatitis-b","20185543":"https:\/\/idw-online.de\/de\/news641587","20218216":"http:\/\/www.vinereport.com\/article\/hepatitis.c.investigations.potential.exposure.in.2nd.u.s.hospital.one.step.testing.developed\/4780.htm","20205539":"http:\/\/www.marketwatch.com\/story\/janssen-presents-new-data-assessing-olysio-simeprevir-in-combination-with-sofosbuvir-in-genotype-4-infected-hcv-patients-in-egypt-2015-11-16","20178537":"http:\/\/finance.yahoo.com\/news\/janssen-presents-data-assessing-olysio-104400739.html","20179937":"http:\/\/iberonews.com\/not_det.php?lang=es&notid=58113","20179938":"http:\/\/iberonews.com\/not_det.php?lang=es&notid=58116","20198912":"http:\/\/www.finanztreff.de\/news\/business-wire-janssen-presents-new-data-assessing-olysio-simeprevir-in-combination-with-so\/10900525","20184287":"http:\/\/pipelinereview.com\/index.php\/2015111659560\/Small-Molecules\/Janssen-Presents-New-Data-Assessing-OLYSIOR-Simeprevir-in-Combination-with-Sofosbuvir-in-Genotype-4-Infected-HCV-Patients-In-Egypt.html","20205842":"http:\/\/www.medicalnewstoday.com\/releases\/302650.php","20198633":"http:\/\/www.eyeontaiwan.com\/childrens-health-booklet-errors-draw-criticism","20193708":"http:\/\/www.businesswire.com\/news\/home\/20151116005544\/en\/Global-Partners-Announce-Donation-500-Millionth-Dose"},"topic":{"20202033":"hepat","20185543":"hepat","20218216":"hepat","20205539":"hepat","20178537":"hepat","20179937":"hepat","20179938":"hepat","20198912":"hepat","20184287":"hepat","20205842":"hepat","20198633":"hepat","20193708":"hepat"},"model1_prediction":{"20202033":1,"20185543":1,"20218216":1,"20205539":1,"20178537":1,"20179937":1,"20179938":1,"20198912":1,"20184287":1,"20205842":1,"20198633":1,"20193708":1},"model1_prediction_prob":{"20202033":0.9657491061,"20185543":0.8773998864,"20218216":0.8766552109,"20205539":0.6947576493,"20178537":0.6708207414,"20179937":0.6694753045,"20179938":0.6637633215,"20198912":0.6492106374,"20184287":0.6488403877,"20205842":0.6109795134,"20198633":0.524517925,"20193708":0.521346973},"title":{"20202033":"Hepatitis B","20185543":"Hepatitis E virus superinfection and clinical progression in hepatitis B patients","20218216":"Hepatitis C investigations:2nd U.S. hospital may be affected; one-step testing developed","20205539":"Janssen Presents New Data Assessing OLYSIO\u00ae (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt","20178537":"Janssen Presents New Data Assessing OLYSIO\u00ae (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt","20179937":"Janssen Presents New Data Assessing OLYSIO\u00ae (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt","20179938":"Pharco Pharmaceuticals Inc. ha anunciado que ravidasvir ha alcanzado una tasa de curaci\u00f3n del 100% cuando se combina con sofosbuvir en pacientes con VHC, sin cirrosis, de genotipo 4","20198912":"Janssen Presents New Data Assessing OLYSIO\u00ae (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt","20184287":"Janssen Presents New Data Assessing OLYSIO(R) (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected HCV Patients In Egypt","20205842":"Large study sums up health issues for new child refugees to US","20198633":"Children\u2019s Health Booklet errors draw criticism","20193708":"Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma"}}